{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:45:10Z","timestamp":1790707510180,"version":"4.1.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cytomegalovirus (CMV) is the leading infectious cause of congenital neurological disabilities. Valacyclovir and CMV hyperimmune globulin (HIG) may reduce vertical transmission and sequelae in neonates. A systematic review on valacyclovir and CMV HIG in preventing vertical transmission or reducing sequelae in neonates was conducted to 3 September 2021. Valacyclovir as a preventive strategy was supported by a well-conducted randomized controlled trial. Evidence supporting valacyclovir as a treatment strategy was limited to observational studies at moderate risk of bias. CMV HIG was not supported as a preventive strategy in 2 randomized controlled trials, which contrasted with observational studies. Evidence favoring CMV HIG as a treatment strategy was limited to observational studies at moderate risk of bias. The role of valacyclovir and CMV HIG in CMV infection in pregnancy is still being defined. Valacyclovir to prevent vertical transmission has the highest quality evidence in favor of use.<\/jats:p>","DOI":"10.1093\/cid\/ciac297","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T11:18:09Z","timestamp":1649935089000},"page":"1467-1480","source":"Crossref","is-referenced-by-count":15,"title":["Describing the Impact of Maternal Hyperimmune Globulin and Valacyclovir on the Outcomes of Cytomegalovirus Infection in Pregnancy: A Systematic Review"],"prefix":"10.1093","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6219-9068","authenticated-orcid":false,"given":"Alyssa","family":"Fitzpatrick","sequence":"first","affiliation":[{"name":"Department of Microbiology and Infectious Diseases, Flinders Medical Centre , Adelaide , Australia"},{"name":"Faculty of Health and Medical Sciences, University of Adelaide , Adelaide , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Cooper","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Women\u2019s and Children\u2019s Hospital , Adelaide , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Vasilunas","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Women\u2019s and Children\u2019s Hospital , Adelaide , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Ritchie","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Women\u2019s and Children\u2019s Hospital , Adelaide , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,19]]},"reference":[{"key":"2022101219174429000_ciac297-B1","volume-title":"Cytomegalovirus","author":"Department for Health and Ageing, Government of South Australia","year":"2018"},{"key":"2022101219174429000_ciac297-B2","first-page":"1385","article-title":"Newborn screening for congenital cytomegalovirus infection\u2026it is time","volume":"70","author":"Demmler","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022101219174429000_ciac297-B3","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0140-6736(20)31868-7","article-title":"Valaciclovir to prevent vertical transmission of cytomegalovirus after maternal primary infection during pregnancy: a randomised, double-blind, placebo-controlled trial","volume":"396","author":"Shahar-Nissan","year":"2020","journal-title":"Lancet"},{"key":"2022101219174429000_ciac297-B4","volume-title":"Management of perinatal infections","author":"Palasanthiran","year":"2014"},{"key":"2022101219174429000_ciac297-B5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/cid\/cis423","article-title":"Early primary CMV infection in pregnancy: maternal hyperimmunoglobulin therapy improves outcomes among infants at 1 year of age","volume":"55","author":"Visentin","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2022101219174429000_ciac297-B6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0022-3476(03)00192-6","article-title":"Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial","volume":"143","author":"Kimberlin","year":"2003","journal-title":"J Pediatr"},{"issue":"Suppl 4","key":"2022101219174429000_ciac297-B7","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.jcv.2009.08.012","article-title":"Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system","volume":"46","author":"Oliver","year":"2009","journal-title":"J Clin Virol"},{"key":"2022101219174429000_ciac297-B8","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJMoa1404599","article-title":"Valganciclovir for symptomatic congenital cytomegalovirus disease","volume":"372","author":"Kimberlin","year":"2015","journal-title":"N Engl J Med"},{"key":"2022101219174429000_ciac297-B9","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2022101219174429000_ciac297-B10","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2022101219174429000_ciac297-B11","doi-asserted-by":"crossref","first-page":"104351","DOI":"10.1016\/j.jcv.2020.104351","article-title":"Valacyclovir in primary maternal CMV infection for prevention of vertical transmission: a case-series","volume":"127","author":"De Santis","year":"2020","journal-title":"J Clin Virol"},{"key":"2022101219174429000_ciac297-B12","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/uog.23685","article-title":"Secondary prevention of congenital cytomegalovirus infection with valacyclovir following maternal primary infection in early pregnancy","volume":"58","author":"Faure-Bardon","year":"2021","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2022101219174429000_ciac297-B13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jogoh.2019.01.003","article-title":"Case report on early treatment with valaciclovir after maternal primary cytomegalovirus infection","volume":"48","author":"Codaccioni","year":"2019","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"2022101219174429000_ciac297-B14","doi-asserted-by":"crossref","first-page":"462.e1","DOI":"10.1016\/j.ajog.2016.04.003","article-title":"In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study","volume":"215","author":"Leruez-Ville","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"2022101219174429000_ciac297-B15","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1471-0528.2007.01308.x","article-title":"Maternal administration of valaciclovir in symptomatic intrauterine cytomegalovirus infection","volume":"114","author":"Jacquemard","year":"2007","journal-title":"BJOG"},{"key":"2022101219174429000_ciac297-B16","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jinf.2019.08.015","article-title":"Prenatal valacyclovir treatment of fetal cytomegalovirus infection: a case series","volume":"79","author":"De Santis","year":"2019","journal-title":"J Infect"},{"key":"2022101219174429000_ciac297-B17","doi-asserted-by":"publisher","DOI":"10.1080\/14767058.2020.1815188","article-title":"Combined treatment with immunoglobulin and valaciclovir in pregnant women with cytomegalovirus infection and high risk of symptomatic fetal disease [manuscript published online ahead of print 15 September 2020]","author":"De la Calle","year":"2020","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2022101219174429000_ciac297-B18","doi-asserted-by":"crossref","first-page":"e242712","DOI":"10.1136\/bcr-2021-242712","article-title":"Congenital cytomegalovirus infection in twin pregnancy","volume":"14","author":"Carvalho","year":"2021","journal-title":"BMJ Case Rep"},{"key":"2022101219174429000_ciac297-B19","doi-asserted-by":"crossref","first-page":"E52","DOI":"10.1055\/a-0591-5981","article-title":"Cytomegalovirus infection in one fetus with hypoplasia of the pons in a diamniotic-dichorionic twin pregnancy","volume":"4","author":"Altmann","year":"2018","journal-title":"Ultrasound Int Open"},{"key":"2022101219174429000_ciac297-B20","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1913569","article-title":"A trial of hyperimmune globulin to prevent congenital cytomegalovirus infection","volume":"385","author":"Hughes","year":"2021","journal-title":"N Engl J Med"},{"key":"2022101219174429000_ciac297-B21","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1056\/NEJMoa1310214","article-title":"A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus","volume":"370","author":"Revello","year":"2014","journal-title":"N Engl J Med"},{"key":"2022101219174429000_ciac297-B22","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/uog.19164","article-title":"Prevention of maternal-fetal transmission of cytomegalovirus after primary maternal infection in the first trimester by biweekly hyperimmunoglobulin administration","volume":"53","author":"Kagan","year":"2019","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2022101219174429000_ciac297-B23","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/cid\/ciz1030","article-title":"High-dose cytomegalovirus (CMV) hyperimmune globulin and maternal CMV DNAemia independently predict infant outcome in pregnant women with a primary CMV infection","volume":"71","author":"Nigro","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022101219174429000_ciac297-B24","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJMoa043337","article-title":"Passive immunization during pregnancy for congenital cytomegalovirus infection","volume":"353","author":"Nigro","year":"2005","journal-title":"N Engl J Med"},{"key":"2022101219174429000_ciac297-B25","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1080\/14767058.2017.1387890","article-title":"Prevention and treatment of fetal cytomegalovirus infection with cytomegalovirus hyperimmune globulin: a multicenter study in Madrid","volume":"32","author":"Bl\u00e1zquez-Gamero","year":"2019","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2022101219174429000_ciac297-B26","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1515\/jpm-2011-0257","article-title":"Use of cytomegalovirus hyperimmunoglobulin for prevention of congenital cytomegalovirus disease: a retrospective analysis","volume":"40","author":"Buxmann","year":"2012","journal-title":"J Perinat Med"},{"key":"2022101219174429000_ciac297-B27","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s00404-018-4703-y","article-title":"No evidence of obstetrical adverse events after hyperimmune globulin application for primary cytomegalovirus infection in pregnancy: experience from a single centre","volume":"297","author":"Chiaie","year":"2018","journal-title":"Arch Gynecol Obstet"},{"key":"2022101219174429000_ciac297-B28","first-page":"294A","article-title":"S-082: prenatal treatment of cytomegalovirus infection with maternal hyperimmune globulin","volume":"20","author":"Gallo","year":"2013","journal-title":"Reprod Sci"},{"key":"2022101219174429000_ciac297-B29","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00404-020-05728-7","article-title":"Fetal and maternal outcome after hyperimmunoglobulin administration for prevention of maternal-fetal transmission of cytomegalovirus during pregnancy: retrospective cohort analysis","volume":"302","author":"Seidel","year":"2020","journal-title":"Arch Gynecol Obstet"},{"key":"2022101219174429000_ciac297-B30","first-page":"E25","article-title":"Prophylactic intravenous immunoglobulin injections to mothers with primary cytomegalovirus infection","volume":"60","author":"Tanimura","year":"2014","journal-title":"Kobe J Med Sci"},{"key":"2022101219174429000_ciac297-B31","first-page":"S98","article-title":"CMV infection in pregnancy: prevention of vertical transmission by means of specific immunoglobulin therapy (CMV-IgG)","volume":"66","author":"Taverna","year":"2009","journal-title":"Pediatr Res"},{"key":"2022101219174429000_ciac297-B32","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.1016\/j.ajog.2013.10.459","article-title":"426: Use of cytomegalovirus hyperimmunoglobulin for prevention of congenital cytomegalovirus disease","volume":"210","author":"De la Calle","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"2022101219174429000_ciac297-B33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/infdis\/jir718","article-title":"Immunoglobulin therapy of fetal cytomegalovirus infection occurring in the first half of pregnancy\u2014a case-control study of the outcome in children","volume":"205","author":"Nigro","year":"2012","journal-title":"J Infect Dis"},{"key":"2022101219174429000_ciac297-B34","first-page":"73","article-title":"A trial of immunoglobulin fetal therapy for symptomatic congenital cytomegalovirus infection","volume":"95","author":"Japanese Congenital Cytomegalovirus Infection Immunoglobulin Fetal Therapy Study Group","year":"2012","journal-title":"J Reprod Immunol"},{"key":"2022101219174429000_ciac297-B35","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1080\/14767058.2017.1338259","article-title":"Successful treatment of intrauterine cytomegalovirus infection with an intraventricular cyst in a dichorionic diamniotic twin gestation using cytomegalovirus immunoglobulin","volume":"31","author":"De la Calle","year":"2018","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2022101219174429000_ciac297-B36","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/pd.1954","article-title":"Treatment of second trimester fetal cytomegalovirus infection with maternal HIG","volume":"28","author":"Moise","year":"2008","journal-title":"Prenat Diagn"},{"key":"2022101219174429000_ciac297-B37","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S0002-9378(99)70620-4","article-title":"Hyperimmunoglobulin therapy for a twin fetus with cytomegalovirus infection and growth restriction","volume":"180","author":"Nigro","year":"1999","journal-title":"Am J Obstet Gynecol"},{"key":"2022101219174429000_ciac297-B38","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1447-0756.2007.00637.x","article-title":"Intrauterine therapy with cytomegalovirus hyperimmunoglobulin for a fetus congenitally infected with cytomegalovirus","volume":"33","author":"Sato","year":"2007","journal-title":"J Obstet Gynaecol Res"},{"key":"2022101219174429000_ciac297-B39","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1093\/cid\/ciz1036","article-title":"The value of hyperimmune globulin in pregnancies complicated by cytomegalovirus infection: a continuing saga","volume":"71","author":"Schleiss","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022101219174429000_ciac297-B40","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/cid\/ciy1128","article-title":"Sequelae of congenital cytomegalovirus infection following maternal primary infections are limited to those acquired in the first trimester of pregnancy","volume":"69","author":"Faure-Bardon","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022101219174429000_ciac297-B41","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/1471-0528.16966","article-title":"Leaning towards cytomegalovirus serological screening in pregnancy to prevent congenital infection: a cost-effectiveness perspective","volume":"129","author":"Seror","year":"2022","journal-title":"BJOG"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac297\/44265391\/ciac297.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/8\/1467\/46468654\/ciac297.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/8\/1467\/46468654\/ciac297.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T19:18:28Z","timestamp":1665602308000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/75\/8\/1467\/6570695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,19]]},"references-count":41,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,4,19]]},"published-print":{"date-parts":[[2022,10,12]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac297","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,15]]},"published":{"date-parts":[[2022,4,19]]}}}